Clinical trial · no report yet · Phase 3
NCT02273375
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
- NCT02273375 ↗
- Completed
- Canadian Cancer Trials Group
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- MEDI4736; Placebo
- Arms
- MEDI4736 · Experimental
- Placebo · Placebo comparator
- Enrollment
- 1,415
- Primary outcomes
- Compare Disease Free Survival (DFS) for Patients With NSCLC That is PD-L1 Expression TC ≥ 25% and Patients Without EGFR Exon 21 L858R Mutation or Exon 19 Deletions or ALK Gene Rearrangements
- Sponsor
- Canadian Cancer Trials Group with Intergroupe Francophone de Cancerologie Thoracique, Thoracic Oncology Group of Australasia (TOGA), National Health and Medical Research Council, Australia, National Cancer Institute, Naples, Central and Eastern European Oncology Group, Dutch Society of Physicians for Pulmonology and Tuberculosis, Korean Cancer Study Group, Fundación GECP, West Japan Oncology Group, Chinese Thoracic Oncology Group
- Start
- Feb 24, 2015
- Primary completion
- Jul 23, 2025
- Results posted
- Yes
- Registry record
- NCT02273375 · updated Sep 14, 2026
Publications
linked from the registry- Glenwood D. Goss, MD, FCP(SA), FRCPC 1; Gail E. Darling, MD, FRCS 2 ; Virginie Westeel, MD 3; Kazuhiko Nakagawa, MD, PhD 4; Bartomeu Massut´ı, MD 5 ; Francesco Perrone, MD 6 ; Sue-Anne McLachlan, MBBS, FRACP 7 ; Jin Hyoung Kang, MD 8 ; Yi-Long Wu, MD 9; Anne-Marie C. Dingemans, MD, PhD 10 ; Rafal Dziadziuszko, MD, PhD 11 ; Laurent Greillier, MD, PhD 12 ; Morihito Okada, MD 13 ; Clarisse Audigier-Valette, MD 14 ; Shunichi Sugawara, MD 15 ; Ernest Nadal, MD, PhD 16 ; Annamaria Catino, MD 17;Anne-Claire Toffart, MD, PhD 18 ; Tetsuya Mitsudomi, MD, PhD 19; Renaud Whittom, MD, FRCPC 20 ; Manuel Domine, MD 21; Nobuyuki Yamamoto, MD 22 ; Olivier Molinier, MD 23 ; Franck Morin, MSc 24 ; Penelope A. Bradbury, MD 25 ; Martin R. Stockler, MBBS, FRACP 26 ; Keyue Ding, PhD 27 ; and Christopher J. O'Callaghan, PhD, DVM 27
- Goss GD, Darling GE, Westeel V, Nakagawa K, Massuti B, Perrone F, McLachlan SA, Kang JH, Wu YL, Dingemans AC, Dziadziuszko R, Greillier L, Okada M, Audigier-Valette C, Sugawara S, Nadal E, Catino A, Toffart AC, Mitsudomi T, Whittom R, Domine M, Yamamoto N, Molinier O, Morin F, Bradbury PA, Stockler MR, Ding K, O'Callaghan CJ. Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. J Clin Oncol. 2026 Mar;44(7):553-564. doi: 10.1200/JCO-25-01828. Epub 2026 Jan 13. PubMed 41529222